Latest Research
12 Articles
Study Finds Rare Immunotherapy Exceptional Responders
Immunotherapy is not very effective against pancreatic cancer, but Dr. Jordan Winter is taking a closer look at patients who benefitted to see what’s different about them.
PASS-01 Trial Results: Filling the Gaps in Personalized Medicine
The PASS-01 trial results provide data to help clarify how the subtypes of pancreatic cancer respond to the two main treatment protocols.
PLATINUM Clinical Trial Actively Recruiting
The PLATINUM clinical trial, for patients with BRCA and PALB2 mutations, seeks participants. Dr. Andrew Ko outlines the trial.
“Off-the-Shelf” Vaccine Improves Overall and Average Relapse Survival
Dr. Zev Wainberg provides an update on the effectiveness of a vaccine, with results showing it extends the time to relapse in many patients.
New Pain Control Technology for Locally Advanced Pancreatic Cancer
Dr. Hani Babiker outlines the results of the PANOVA-3 trial, which tested Tumor Treating Fields and chemotherapy for pain control.
Advances in Pancreatic Neuroendocrine Tumor (PNET) Treatments
Dr. Diane Reidy-Lagunes outlines the current state of treatments for pancreatic neuroendocrine tumors (PNETs).
Treating Cancer By Mutation, Not by Tumor Location
Dr. Conan Kinsey outlines the latest basket trials, which focus on tumor mutation, not the location of the cancer.
Pancreatic Cancer Research Highlights from ASCO Annual Meeting
The 2025 ASCO meeting featured pancreatic cancer research including a new treatment modality and a new treatment combination.
RASolute 302 Trial for KRAS and Other RAS Mutations Recruiting at Multiple Sites
Dr. Hani Babiker is optimistic about the new drug to treat patients with KRAS mutations, now in a phase III trial.
Highlights from the 2025 AACR Annual Meeting
Drugs to target KRAS, better imaging for earlier detection, and cachexia prediction are among the research highlights from AACR 2025.
Phase II/III Clinical Trial Recruiting Advanced Pancreatic Cancer Patients
Dr. Shalini Makawita is a primary investigator in a phase IIb/III immunotherapy clinical trial for advanced pancreatic cancer patients.
New Phase III Clinical Trial Actively Recruiting
Dr. Zev Wainberg is enthusiastic about the phase III clinical trial combining a new drug and standard chemo to make immunotherapy more effective.